Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of IL-1β inhibitor canakinumab (Ilaris®) on IL-6 production in human skeletal muscle cells.

PloS one·2025
Same author

Selective retinoid X receptor agonism promotes functional recovery and myelin repair in experimental autoimmune encephalomyelitis.

Acta neuropathologica communications·2024
Same author

Supramolecular delivery of dinuclear ruthenium and osmium MCU inhibitors.

Inorganic chemistry frontiers·2024
Same author

The mitochondrial calcium uniporter inhibitor Ru265 increases neuronal excitability and reduces neurotransmission via off-target effects.

British journal of pharmacology·2024
Same author

Reducing wait times and avoiding unnecessary use of high-cost mental health services through a Rapid Access and Stabilization Program: protocol for a program evaluation study.

BMC health services research·2024
Same author

Preserving and enhancing mitochondrial function after stroke to protect and repair the neurovascular unit: novel opportunities for nanoparticle-based drug delivery.

Frontiers in cellular neuroscience·2023

Related Experiment Video

Updated: May 21, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

New methods for multiple sclerosis drug discovery.

Jordan Warford1, George S Robertson

  • 1Dalhousie University , Department of Pharmacology , Halifax, NS B3H 1X5 , Canada.

Expert Opinion on Drug Discovery
|June 2, 2012
PubMed
Summary
This summary is machine-generated.

Inhibitor of apoptosis (IAP) proteins contribute to multiple sclerosis (MS) by preventing the natural death of harmful immune cells. Targeting IAPs offers a promising strategy for developing new MS therapies and diagnostics.

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: May 21, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

  • Neuroimmunology
  • Apoptosis Research
  • Disease Pathogenesis

Background:

  • Multiple sclerosis (MS) is a complex neurological disorder with heterogeneous subtypes.
  • Autoreactive immune cells resist apoptosis, contributing to MS susceptibility and progression.
  • The inhibitor of apoptosis (IAP) protein family plays a key role in this resistance.

Purpose of the Study:

  • To explore the role of IAP proteins in MS pathogenesis.
  • To identify improved animal models for MS research.
  • To develop novel therapeutic strategies targeting apoptosis in MS.

Main Methods:

  • Utilizing improved animal modeling strategies.
  • Investigating immunomodulatory, neurorestorative, and neuroprotective compounds.
  • Developing new approaches to model cognitive dysfunction in MS.

Main Results:

  • Elevated IAP levels are linked to distinct MS subtypes.
  • IAP overexpression in animal models offers insights into MS pathogenesis.
  • Apoptosis-related proteins show diagnostic and therapeutic potential for MS.

Conclusions:

  • Targeting IAP family members can lead to improved MS therapeutics.
  • Detection and targeting of IAPs may offer better diagnostic tools for MS subtypes.
  • Overexpression of IAPs in animal models can accelerate the discovery of new MS treatments.